
Researchers at Brigham and Women’s Hospital in Boston are urging that U.S. HIV-treatment guidelines be changed to include drug-resistance testing for all HIV patients before antiretroviral therapy is initiated because of the likelihood that they may have been infected with virus already resistant to one or more anti-HIV drugs. Currently, drug-resistance tests are usually offered only to HIV patients who are experiencing treatment failure to help pinpoint which of their medications is no longer effective in stopping HIV replication. Pretreatment testing both improves the survival of patients and is cost-effective, the researchers write in the November 1 issue of the journal Clinical Infectious Diseases, which is now available online.
Using a computer model comparing patient survival times and cost of drug-resistance testing, the researchers discovered that frontline testing increased patient survival by up to 15 months and was highly cost-effective compared with other tests and intervention routines done for both HIV-positive and HIV-negative patients.
"Unfortunately, HIV drug resistance, which now is found in 8% to 10% of all newly diagnosed HIV patients, is on the rise," says researcher Paul Sax in a press release. "The good news today is that we have demonstrated resistance testing at the time of diagnosis—before treatment begins—is a strategy that can increase survival at a very reasonable cost to patients, hospitals, and insurers."
The resistance test BWH currently uses costs approximately $400, and it is likely to continue dropping in price, according to Sax. This up-front cost is less than 0.2% of the total lifetime cost of caring for an HIV-positive person, making the test extremely cost-effective.
"With more than 20 anti-HIV medications currently available, genotype resistance testing prior to the start of therapy can help offer patients an individualized treatment plan," says Sax in a press release. "Based on our cost-effectiveness model, we are urging HIV clinicians to consider testing for resistance in untreated patients right away at the time of diagnosis. Patients should also talk to their doctors about this new approach. There is no longer a good reason to wait."
The study was funded by the National Institutes of Health and the Centers for Disease Control and Prevention. (Advocate.com)
These comments are reproduced as written by visitors to this Web site. They have not been edited for content, grammar, or spelling. The viewpoints appearing here are those of the writer, and do not necessarily reflect the opinion or views of advocate.com, The Advocate, or its affiliates.
Be the first to comment on this story.
If you would like to submit a comment for posting, please fill out the form above.
All comments submitted via this form are subject to posting or publication. (To send a private letter to an Advocate editor or writer, please use the e-mail button at the top of the page, or use snail mail.) If you would like your comment considered for publication in The Advocate magazine, please include your full name, your city of residence, and a phone number where you can be reached during business hours so that we can confirm your identity. Your e-mail address and telephone number are strictly confidential and will not be shared or used for any purpose other than to contact you about your comment.
Comments that do not concern specific articles in The Advocate or on Advocate.com will not be posted or published. See the Contact page for sending comments for reasons other than responding to Advocate editorial and news stories.
Please note that comments sent by fax or snail mail are unlikely to be posted, although they will be considered for publication along with all letters received via e-mail or via this Web page. Comments that chiefly concern Advocate.com content will be considered for posting only on the Web site. The Advocate reserves the right to edit submitted comments for grammar, spelling, obscenities, or libel; we will, however, do our best to preserve the original comment's style and intent. Comments considered for publication in The Advocate magazine may also be edited for length.